Publications
- Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma2023 | First Faculty of Medicine
- Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy2023 | First Faculty of Medicine, Second Faculty of Medicine
- Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas2022 | Faculty of Physical Education and Sport, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas2022 | First Faculty of Medicine
- Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma2021 | First Faculty of Medicine
- Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells2020 | First Faculty of Medicine, Second Faculty of Medicine
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Current Immunotherapy Approaches in Non-Hodgkin Lymphomas2020 | First Faculty of Medicine
- PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population2020 | First Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...